use
target
mitig
influenza
viru
iav
use
synthet
mrnabas
platform
crispr
rna
crrna
highli
conserv
region
screen
conjunct
mrnaencod
screen
design
guid
decreas
influenza
rna
level
fashion
valid
mrna
valid
guid
deliv
postinfect
simul
treatment
test
combin
across
multipl
infect
function
also
character
time
similar
screen
perform
guid
yield
multipl
guid
significantli
impact
cytopath
effect
last
approach
util
vivo
demonstr
abil
degrad
influenza
rna
mous
model
infect
use
polymerformul
nebulizerbas
mrna
deliveri
find
demonstr
applic
mitig
respiratori
infect
vitro
mous
model
pave
way
futur
therapeut
use
speci
virus
known
infect
human
rna
virus
estim
viral
infect
contribut
approxim
global
mortal
especi
concern
given
approxim
drug
sinc
treat
viral
speci
addit
approv
vaccin
viral
speci
reassort
antigen
shift
drift
influenza
well
antibodi
depend
enhanc
ade
sar
possibl
pose
challeng
vaccin
develop
factor
like
contribut
epidem
pandem
human
health
thu
constant
threat
due
emerg
reemerg
viral
infect
outbreak
zika
ebola
current
pandem
potenti
futur
influenza
pandem
warrant
develop
new
class
antivir
drug
current
drug
develop
focus
small
molecul
neutral
antibodi
requir
high
dose
frequent
redos
obtain
function
outcom
thu
crucial
address
need
antivir
broad
spectrum
flexibl
effect
across
multipl
viral
speci
strain
discoveri
rna
target
class
ii
type
vi
crisprca
system
bacteria
engend
tremend
interest
potenti
applic
crrna
complex
activ
target
rna
trrna
complement
crrna
ca
protein
initi
rna
cleavag
due
higher
eukaryot
prokaryot
nucleotidebind
hepn
domain
properti
use
detect
specif
transcript
mixtur
nucleic
acid
specif
rnase
activ
also
use
knockdown
endogen
gene
recent
two
group
demonstr
abil
degrad
influenza
rna
case
transient
transfect
plasmid
stabl
cell
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
line
express
use
prophylact
influenza
rna
case
express
least
hr
prior
infect
prior
work
clearli
use
demonstr
proof
principl
examin
crucial
step
toward
use
approach
treatment
respiratori
viral
infect
given
advantag
transient
express
treat
infect
develop
synthet
mrna
express
without
nl
sequenc
influenza
rna
local
compart
differ
time
postinfect
construct
test
function
within
intub
assay
synthet
mrna
synthet
mrna
express
transient
littl
chanc
integr
innat
immun
respons
mitig
sequenc
design
modifi
nucleotid
purif
addit
given
mrnabas
approach
initi
benchmark
examin
knockdown
endogen
gene
use
previous
publish
target
region
examin
gene
expand
number
control
use
found
knockdown
rna
mediat
number
control
need
ensur
knockdown
mediat
enzymat
action
occur
determin
control
import
guid
screen
via
qpcr
given
postinfect
simul
treatment
strategi
polymeras
gene
highli
conserv
without
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
polymeras
protein
neither
viral
mrna
replic
occur
potent
guid
mrna
found
use
approach
guid
broader
sequenc
homolog
across
flu
strain
sought
first
examin
homolog
among
vaccin
strain
stretch
nucleotid
found
overlap
strain
pandem
strain
strain
use
prior
vaccin
vaccin
strain
benchmark
circul
strain
variat
time
thu
good
candid
least
two
potent
guid
sequenc
found
subsequ
test
postinfect
includ
combin
guid
timecours
studi
yield
potent
knockdown
influenza
rna
ask
whether
approach
could
use
viru
caus
current
pandem
deliv
mrna
prophylact
viru
especi
potent
cell
cytopath
effect
cpe
use
metric
success
demonstr
clear
mitig
cpe
last
demonstr
approach
translat
potenti
deliv
mrna
guid
formul
pbaebas
polym
via
nebul
postinfluenza
infect
simul
treatment
day
post
infect
degrad
influenza
rna
lung
evalu
demonstr
robust
knockdown
overal
feel
demonstr
necess
control
design
crrna
possibl
paninfluenza
target
viral
strain
abil
target
relev
emerg
respiratori
pathogen
vitro
vivo
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
substrat
fluoresc
output
rna
cleavag
rna
cleavag
gener
fluoresc
increas
maximum
initi
period
respect
gradual
decreas
time
like
due
photobleach
overal
trend
rna
cleavag
similar
fig
result
indic
vitro
translat
mediat
rna
cleavag
specif
occur
crrna
trrna
present
addit
nontarget
crrna
ntcr
use
along
trrna
rna
cleavag
observ
thu
demonstr
crrnaspecif
cleavag
trrna
fig
overal
mrna
design
express
function
protein
order
fulli
valid
mrnabas
approach
mrna
express
without
nl
guid
target
ppib
kra
endogen
gene
test
gene
knockdown
evalu
hour
via
qpcr
fig
supplementari
tabl
initi
knockdown
rel
non
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
target
control
rna
ntcr
evalu
effect
transfect
etc
gene
express
assess
date
studi
evalu
target
reduct
rna
rel
reduct
due
ntcr
two
addit
control
ad
mrna
express
dead
inact
plu
target
guid
gfp
encod
mrna
plu
target
guid
control
yield
valuabl
inform
regard
guid
perform
dead
version
give
insight
whether
bindingonli
event
may
affect
rna
level
gfp
control
add
addit
inform
regard
whether
guid
alon
knockdown
effect
control
affect
rna
level
knockdown
due
activ
enzym
enzymat
action
drive
reduct
case
inact
version
may
also
decreas
rna
level
fig
b
necessarili
problem
per
se
control
group
help
distinguish
bind
relat
knockdown
enzymat
effect
inform
import
establish
mode
action
therapeut
approach
ppib
control
gener
act
expect
though
effect
ntcr
nl
case
ppib
guid
exhibit
knockdown
via
cytosol
nl
version
hr
respect
fig
unfortun
guid
use
publish
spacer
sequenc
without
express
significantli
knock
mrna
fig
kra
occur
instead
guid
exhibit
mediat
knockdown
via
cytosol
nl
version
hr
respect
fig
data
result
experi
surpris
clearli
demonstr
need
addit
control
screen
guid
specif
rna
ensur
mediat
knockdown
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
next
six
guid
target
genom
mrna
design
screen
postinfect
supplementari
tabl
expand
breath
guid
influenza
target
clearli
approach
high
therapeut
valu
abil
target
mani
strain
given
viru
advantag
influenza
bioinformat
comparison
influenza
histor
vaccin
strain
candid
vaccin
strain
publicli
avail
genom
sequenc
yield
number
conserv
region
across
differ
subset
strain
fig
specif
focus
socal
human
subset
includ
human
season
human
season
strain
analysi
conserv
region
found
six
guid
design
viral
mrna
genom
influenza
fig
guid
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
exhibit
knockdown
rna
level
fig
supplementari
fig
two
guid
examin
breadth
combin
compar
strain
download
last
year
exact
match
strain
fig
e
f
result
encourag
toward
goal
paninfluenza
approach
mrna
target
guid
combin
cytoplasm
nl
target
combin
evalu
function
moi
overtim
fig
use
combin
nl
cytoplasm
justifi
variabl
distribut
viral
rnp
cell
cell
supplementari
fig
first
combin
evalu
standard
screen
assay
clearli
saw
benefit
combin
yield
lower
rna
valu
alon
combin
examin
across
moi
clear
knockdown
achiev
effect
fig
ab
effect
though
may
increas
enzymat
reaction
given
time
dose
mrna
guid
increas
combin
evalu
time
result
demonstr
continu
rna
reduct
span
hour
fig
cd
peak
differ
iav
ntcr
hour
note
see
increas
effect
ntcr
time
like
due
low
level
ntcr
overlap
nativ
gene
induc
activ
howev
effect
treatment
drug
mrnatarget
guid
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
compar
iav
case
approach
abl
sustain
knockdown
period
given
current
import
set
crrna
target
highli
conserv
region
replicas
nucleocapsid
region
genom
design
fig
repeat
well
plate
use
individu
combin
guid
includ
control
data
quantifi
imag
analysi
demonstr
combin
reduct
cell
death
cell
remain
plate
overal
bode
well
use
therapeut
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
order
test
approach
vivo
first
develop
apparatu
formul
rna
nebulizerbas
deliveri
design
straightforward
nosecon
nebul
apparatu
fig
allow
mice
dose
simultan
vibrat
mesh
nebul
pbae
chosen
formul
base
prior
public
lung
deliveri
first
final
concentr
mrna
formul
optim
use
gpianchor
nanoluciferas
anluc
encod
mrna
lung
fig
yield
optim
express
lung
report
previous
next
determin
whether
influenza
infect
affect
deliveri
infect
mice
influenza
deliv
anluc
mrna
hr
postinfect
well
without
infect
fig
signific
differ
express
observ
demonstr
effici
mrna
deliveri
protein
express
via
nebul
face
influenza
infect
order
test
treatment
approach
mice
infect
analysi
reveal
reduct
viral
rna
ntcr
iav
demonstr
robust
knockdown
viral
rna
vivo
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
rna
virus
pose
challeng
drug
vaccin
develop
thu
global
health
concern
unconvent
molecular
tool
like
rnaactiv
rnase
could
potenti
new
paradigm
therapeut
pathogen
howev
rna
target
rnase
safe
effect
therapeut
use
rapid
transient
express
prefer
achiev
opt
synthet
vitro
transcrib
mrna
express
mrna
advantag
rapid
translat
desir
protein
clearanc
avoid
safeti
concern
genom
integr
unmitig
innat
immun
respons
use
rnabas
approach
found
crrna
guid
target
genom
mrna
influenza
effect
even
given
hour
postinfect
date
first
demonstr
approach
use
postinfect
though
clear
bia
toward
mrna
target
guid
consist
prior
work
use
sirna
influenza
addit
even
though
abl
find
guid
truli
paninfluenza
clearli
overlap
strain
make
signific
stride
toward
goal
prior
studi
target
polymeras
gene
content
excel
target
due
clear
role
gener
viral
rna
fact
well
conserv
also
demonstr
first
time
approach
scale
moi
function
period
even
use
transient
transfect
mrna
time
cours
data
demonstr
abil
degrad
rna
rate
equal
rapidli
rate
rna
gener
viral
replic
address
date
data
clearli
show
period
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
postdeliveri
keep
rna
level
consist
log
lower
without
treatment
futur
address
dose
effect
dynam
may
chang
address
question
approach
rapidli
appli
directli
newli
emerg
pathogen
like
result
clear
signific
effect
cpe
wellestablish
measur
antivir
activ
result
clearli
demonstr
adapt
approach
flexibl
differ
guid
sequenc
suffici
target
either
iav
deliv
nuclear
cytoplasm
version
togeth
replic
dynam
differ
virus
significantli
impact
given
promis
result
vitro
approach
move
anim
model
near
futur
due
need
fact
anim
model
yet
matur
pursu
experi
junctur
last
answer
critic
question
regard
use
vivo
formul
mrna
pbaebas
polym
previous
demonstr
anderson
lab
deliv
postinfect
use
vibratingmesh
style
nebul
current
use
human
simul
treatment
strategi
demonstr
degrad
viral
rna
vivo
effici
first
demonstr
use
anim
model
infect
bode
well
treat
infect
given
guid
effect
vitro
confid
move
appropri
anim
model
ferret
hamster
import
step
toward
develop
base
treatment
strategi
futur
work
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
includ
vital
step
addit
develop
mrna
carrier
lung
overal
work
demonstr
signific
progress
toward
use
treat
respiratori
viral
infect
sequenc
leptotrichia
buccali
obtain
addgen
plasmid
clone
wild
type
tag
append
utr
mous
alphaglobin
genbank
access
vector
geneart
thermo
scientif
usa
addit
synthes
construct
sequenc
leptotrichia
buccali
along
nuclear
local
sequenc
tag
creat
version
use
geneblock
integr
dna
technolog
construct
synthes
catalyticallyinact
version
sequenc
obtain
addgen
plasmid
sequenc
gpi
anchor
nanoluciferas
describ
lindsay
et
al
plasmid
linear
noti
hf
new
england
biolab
overnight
linear
templat
purifi
sodium
acet
thermo
fisher
scientif
precipit
rehydr
nucleas
free
water
ivt
perform
overnight
use
hiscrib
kit
neb
follow
manufactur
instruct
modifi
result
rna
treat
dnase
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
aldevron
min
remov
templat
purifi
use
lithium
chlorid
precipit
thermo
fisher
scientif
rna
heat
denatur
minut
cap
structur
use
guanylyl
transferas
aldevron
mrna
purifi
lithium
chlorid
precipit
treat
alkalin
phosphatas
neb
purifi
mrna
concentr
measur
use
nanodrop
mrna
stock
concentr
mgml
purifi
mrna
product
analyz
gel
electrophoresi
ensur
puriti
crrna
guid
purchas
integr
dna
technolog
idt
genscript
sequenc
detail
supplementari
tabl
order
demonstr
mrnaexpress
effici
encod
fulli
function
enzym
abl
cleav
target
rna
tube
assay
mrna
translat
vitro
use
rabbit
reticulocyt
lysat
system
accord
tabl
mixtur
ad
cold
translat
lysat
plate
well
mix
well
reagent
prepar
addit
perform
ice
fluoresc
measur
excit
nmemiss
nm
record
room
temperatur
min
min
interv
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
tabl
cell
seed
overnight
densiti
per
well
well
plate
follow
day
cell
wash
infect
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
vero
cell
seed
overnight
confluenc
well
plate
methanol
formaldehyd
minut
imag
present
white
balanc
intens
analysi
modifi
calcul
imag
brought
photoshop
convert
grayscal
color
invert
roi
size
use
imag
sum
intens
calcul
voloc
intens
normal
blank
region
imag
order
account
imag
imag
variat
signal
normal
mock
condit
give
percent
live
cell
area
anim
studi
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
sixto
femal
balbc
mice
jackson
laboratori
maintain
pathogenfre
condit
individu
ventil
water
cage
kept
neg
pressur
food
provid
mice
ad
libitum
anim
acclimat
least
day
begin
experi
anim
randomli
distribut
among
experiment
group
research
blind
anim
group
alloc
data
acquisit
anim
sacrif
asphyxi
mice
load
custombuilt
noseonli
exposur
system
construct
clear
pvc
tee
anim
restraint
coda
small
mous
holder
kent
scientif
connect
use
custom
nosecon
print
tech
made
flexibl
tpu
materi
nebul
aeroneb
kent
scientif
place
upward
face
port
tee
dose
ad
dropwis
nebul
rate
individu
droplet
nebul
clear
tee
inspect
vapor
dose
clear
approxim
second
per
drop
droplet
ad
desir
dose
per
anim
achiev
vapor
clear
follow
last
droplet
mice
remov
restraint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
mrna
formul
nebulizerbas
deliveri
use
hyperbranch
pbae
previous
describ
deliveri
mice
mm
sodium
acet
ph
use
solubil
hyperbranch
pbae
dilut
mrna
prior
mix
final
concentr
mrna
mgml
pbae
use
molar
ratio
mrna
tube
incub
rt
minut
particl
load
nebul
describ
follow
euthanasia
whole
lung
collect
rins
pb
lung
place
solut
nanoglo
substrat
solut
promega
dilut
pb
lung
incub
minut
place
onto
black
paper
imag
ivi
spectrum
ct
perkin
elmer
lung
luminesc
quantifi
use
live
imag
softwar
perkin
elmer
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
mice
infect
intranas
influenza
viru
use
per
nostril
follow
brief
anaesthesia
isofluran
viru
dilut
dmem
without
modif
desir
pfu
dose
euthanasia
lung
harvest
pb
prior
downstream
assay
lung
dissoci
describ
previous
briefli
lung
weigh
dissoci
use
gentlemac
c
tube
use
lung
set
miltenyi
centrifug
rt
minut
xg
pellet
lyse
rlt
plu
buffer
qiagen
homogen
use
navi
tube
bullet
blender
next
advanc
lysat
centrifug
min
maximum
speed
clarifi
supernat
total
rna
extract
follow
rneasi
plu
mini
kit
qiagen
per
manufactur
instruct
cdna
synthesi
qpcr
perform
detail
absolut
quantif
viral
gene
copi
number
experi
repres
mean
three
six
biolog
replic
indic
data
analyz
use
graphpad
prism
statist
analys
perform
group
use
either
ordinari
oneway
twoway
analysi
varianc
anova
specifi
individu
figur
caption
data
gener
analys
studi
includ
publish
articl
supplementari
inform
file
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
author
declar
conflict
interest
mediat
knockdown
twoanova
tukey
multipl
comparison
perform
p
p
p
p
c
mediat
kra
knockdown
twoanova
tukey
multipl
comparison
perform
p
p
p
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
oneway
anova
multipl
comparison
ntcr
c
mrna
along
either
guid
alon
indic
combin
transfect
cell
overnight
gfp
mrna
along
guid
use
control
demonstr
catalyt
guid
activ
cell
infect
moi
hpi
crystal
violet
stain
use
assess
cpe
percent
live
cell
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
area
plot
error
bar
indic
sd
indic
indic
oneway
anova
multipl
comparison
ntcr
lung
viral
load
infect
mice
dose
mrna
either
target
ntcr
guid
h
post
infect
one
group
infect
mice
treat
data
repres
mean
fold
chang
sd
ntcr
left
repres
repres
oneway
anova
logtransform
data
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
certifi
peer
review
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
